Technology Listings


Natural Antimicrobial Compound to Treat Multidrug Resistant Infections

Application

Pentagalloylglucose and extracts of Anacardiaceae to treat multidrug resistant bacterial and fungal infections.

Key Benefits
  • Potential compounds to combat multidrug-resistant pathogens.
  • Natural compound isolated from Schinus plants.
  • Antibiotic activity against multidrug-resistant bacteria and fungi.
  • Low likelihood to contribute to multidrug-resistant organisms.
Market Summary

Excessive use and misuse of antibiotics is increasing the prevalence of antibiotic resistance microorganisms. An estimated 70% of bacteria are already resistant to at least one antibiotic that formerly was used to combat them. Six nosocomial pathogens found to exhibit multidrug resistance and virulence are Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter (i.e. ESKAPE pathogens). The CDC’s 2019 antibiotic resistance threats report also lists Candida auris and carbapenem-resistant (CR) Acinetobacter baumannii as urgent threats, and Pseudomonas aeruginosa as a serious threat. In 2017, around 700,000 deaths globally were caused by antimicrobial resistance and this figure is expected to rise to 10 million by 2050 if necessary actions to control antimicrobial resistance are not taken. There are limited antimicrobial agents with potent activity against multidrug-resistant pathogens on the market.

Technical Summary

Researchers from Emory University and Georgia Tech have identified natural compounds to address multi-drug resistant infections. A crude extract of Schinus terebinthifolia leaves used in traditional medicine for wounds, ulcers, and fungal infections exhibited growth inhibition of CR A. baumannii, Pseudomonas aeruginosa and Candida spp. Bioassay-guided fractionation of the extract further led to the isolation of a bioactive gallotannin. In mammalian cytotoxicity assays, the compound demonstrated growth inhibition of several ESKAPE pathogens, as well as C. auris, P. aeruginosa, CR A. baumannii, and Staphylococcus aureus.

Developmental Stage

Compounds have been isolated and tested in vitro.

Publications: Dettweiler, M. et al. (2020). Sci Rep, 10(1), 15340.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
PCT PCT PCT/US2021/019873   2/26/2021   8/28/2022 Pending
Tech ID: 20102
Published: 12/9/2020
Category
Therapeutics

Contact
Jessica Beach
Marketing Specialist
Emory University, Office of Technology Transfer
(404) 727-1899
jbeach4@emory.edu

Inventor(s)
Cassandra Quave
Francois Chassagne
Lewis Marquez
Micah Dettweiler
Julia Kubanek
Anne Sweeney-Jones
Bhuwan Chhetri

Keywords
Biologic
Microbiology/Infectious Diseases